Brief: Vanda Pharmaceuticals Says FDA To Expedite Re-review Of Tradipitant By Nov 26

Vanda Pharmaceuticals

01/10/2025 22:09

Oct 1 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:

VANDA PHARMACEUTICALS ANNOUNCES COLLABORATIVE FRAMEWORK FOR RESOLUTION OF DISPUTES WITH THE U.S. FOOD AND DRUG ADMINISTRATION

VANDA PHARMACEUTICALS INC - FDA TO EXPEDITE RE-REVIEW OF TRADIPITANT BY NOV 26, 2025

VANDA PHARMACEUTICALS INC - FDA TO EXPEDITE RE-REVIEW OF HETLIOZ SNDA BY JAN 7, 2026

VANDA PHARMACEUTICALS INC - FDA AND VANDA TO SEEK PAUSE OF TRADIPITANT NDA PROCEEDINGS UNTIL JAN 7, 2026

VANDA PHARMACEUTICALS INC - TO DISMISS LAWSUIT ON HETLIOZ EFFICACY INFORMATION

VANDA PHARMACEUTICALS INC - TO DISMISS LAWSUIT CHALLENGING FDA'S CLINICAL HOLD ON TRADIPITANT

Source text: ID:nPn7P77B0a

Further company coverage: VNDA.O

 ((Reuters.Briefs@thomsonreuters.com;))